Compound: Benzetimide
SMILES: O=C1NC(=O)CCC1(c2ccccc2)C3CCN(Cc4ccccc4)CC3
InChIKey: LQQIVYSCPWCSSD-UHFFFAOYSA-N
Synonyms: Benzetimide, 14051-33-3, Benzetimidum, Spasmental, bencetimida, 2-(1-Benzyl-4-piperidyl)-2-phenylglutarimide, B987T0L5FX, DTXSID2046173, 2-[1-BENZYL-4-PIPERIDYL]-2-PHENYLGLUTARIMIDE, DTXCID0026173, (3,4'-Bipiperidine)-2,6-dione, 3-phenyl-1'-(phenylmethyl)-, RefChem:118121, Benzetimide [INN], 3-(1-benzylpiperidin-4-yl)-3-phenylpiperidine-2,6-dione, Benzetimide (INN), 1'-Benzyl-3-phenyl-[3,4'-bipiperidine]-2,6-dione, 119391-55-8, CHEMBL10272, MFCD00242705, (+/-)-Benzetimide, 3-(1-benzyl-4-piperidyl)-3-phenyl-piperidine-2,6-dione, NCGC00160474-01, Benzezimida, (+-)-Benzetimide, Benzetimidum [INN-Latin], Benzezimida [INN-Spanish], UNII-B987T0L5FX, Dextrobenzetimide, ()-Benzetimide, [3,4'-Bipiperidine]-2,6-dione,3-phenyl-1'-(phenylmethyl)-, BENZETIMIDE [MI], 1''-Benzyl-3-phenyl-[3,4'']bipiperidinyl-2,6-dione, SCHEMBL148330, Spasmental [veterinary] (TN), CHEBI:188883, LQQIVYSCPWCSSD-UHFFFAOYSA-N, (RS)-3-(1-Benzyl-4-piperidyl)-3-phenyl-2,6-piperidindion, EX-A3066, WAA88899, Tox21_111838, BDBM50018556, MFCD00210783, AKOS005066173, NCGC00160474-02, DA-61576, SY492235, CAS-14051-33-3, EU-0015149, NS00007939, NS00100852, D07513, L001340, 1'-Benzyl-3-phenyl[3,4'-bipiperidine]-2,6-dione, Q27274534, (+)-1''-benzyl-3-phenyl-3,4''-bipiperidine-2,6-dione, (-)-1''-benzyl-3-phenyl-3,4''-bipiperidine-2,6-dione, (+/-)-1''-benzyl-3-phenyl-3,4''-bipiperidine-2,6-dione, Dexetimide1''-Benzyl-3-phenyl-[3,4'']bipiperidinyl-2,6-dione
Theoretical properties:
molecular_formula: C23H26N2O2
molecular_weight: 362.5 g/mol
exact_mass: 362.199428076 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 4
heavy_atom_count: 27
topological_polar_surface_area: 49.4 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Benzetimide is a member of piperidines.
chembl: BENZETIMIDE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 2.0.
wikipedia: From 1948 to 1975, the U.S. Army Chemical Corps conducted classified human subject research at the Edgewood Arsenal facility in Maryland. These experiments began after the conclusion of World War II, and continued until the public became aware of the experiments, resulting in significant outcry. The purpose was to evaluate the impact of low-dose chemical warfare agents on military personnel and to test protective clothing, pharmaceuticals, and vaccines. A small portion of these studies were directed at psychochemical warfare; grouped under the title "Medical Research Volunteer Program" (1956–1975), driven by intelligence requirements and the need for new and more effective interrogation techniques.
Overall, about 6,720 soldiers took part in these experiments that involved exposures to more than 250 different chemicals, according to the Department of Defense (DoD). Some of the volunteers exhibited symptoms at the time of exposure to these agents but long-term follow-up was not planned as part of the DoD studies. The experiments were abruptly terminated by the Army in late 1975 amidst an atmosphere of scandal and recrimination as lawmakers accused researchers of questionable ethics. Many official government reports and civilian lawsuits followed in the wake of the controversy.
The chemical agents tested on volunteers included chemical warfare agents and other related agents:

Anticholinesterase nerve agents (VX, sarin) and common organophosphorus (OP) and carbamate pesticides
Mustard agents
Nerve agent antidotes including atropine and scopolamine
Nerve agent reactivators, e.g. the common OP antidote 2-PAM chloride
Psychoactive agents including LSD, PCP, cannabinoids, and BZ
Irritants and riot control agents
Alcohol and caffeine